Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16713057 | 0.92 | CYP1A2 (0.66) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| SCHEMBL631023 | 0.86 | ALDH1A1 (0.66) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| SCHEMBL4603241 | 0.85 | MEN1 (0.59) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| SCHEMBL4603238 | 0.85 | MEN1 (0.59) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| SCHEMBL11579350 | 0.85 | LDHA (0.58) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| SCHEMBL8529164 | 0.83 | MEN1 (0.54) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| SCHEMBL1127532 | 0.83 | MEN1 (0.54) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| SCHEMBL9771325 | 0.83 | MEN1 (0.54) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL8976504 | 0.83 | MEN1 (0.57) | MEN1KMT2ALTA4HCYP1A2CYP2D6 | |
| SCHEMBL9232177 | 0.83 | MEN1 (0.54) | MEN1KMT2ALTA4HCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1077 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332489-B2 | Process for preparing imetelstat | GERON CORPORATION (US) | 2022-05-17 | — | — | US | claimed |
| EP-3652187-B1 | IMPROVED PROCESS FOR PREPARING IMETELSTAT | GERON CORP (US) | 2021-09-15 | — | — | EP | claimed |
| US-20200369702-A1 | Improved Process for Preparing Imetelstat | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2020-11-26 | — | — | US | claimed |
| EP-3652187-A1 | IMPROVED PROCESS FOR PREPARING IMETELSTAT | GERON CORPORATION (US) | 2020-05-20 | — | — | EP | claimed |
| CN-110891961-A | Improved process for the preparation of isomestat (imetelstat) | 美国杰龙生物医药公司 | 2020-03-17 | — | — | CN | claimed |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2019-03-26 | — | — | US | claimed |
| WO-2019011829-A1 | IMPROVED PROCESS FOR PREPARING IMETELSTAT | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-17 | — | — | WO | claimed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | claimed |
| EP-3330277-A2 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | claimed |
| US-4849513-A | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1989-07-18 | — | — | US | claimed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | claimed |
| EP-0285254-A1 | Antihypercholesterolemic betalactones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | claimed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | claimed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | claimed |
| EP-0061746-B1 | PHOSPHORAMIDITE COMPOUNDS AND THEIR USE IN PRODUCING OLIGONUCLEOTIDES | UNIVERSITY PATENTS, INC. (US) | 1985-03-20 | — | — | EP | claimed |
| EP-0035255-B1 | PROCESS FOR REMOVING TRITYL BLOCKING GROUPS FROM 5'-O TRITYL NUCLEOSIDES AND OLIGONUCLEOTIDES | UNIVERSITY PATENTS, INC. (US) | 1984-05-30 | — | — | EP | claimed |
| US-4415732-A | STORAGE-STABLE NUCLEOSIDES; POLYNUCLEOTIDE SYNTHESIS | UNIVERSITY PATENTS, INC. (US) | 1983-11-15 | — | — | US | claimed |
| EP-0061746-A1 | Phosphoramidite compounds and their use in producing oligonucleotides | UNIVERSITY PATENTS, INC. (US) | 1982-10-06 | — | — | EP | claimed |
| EP-0035255-A1 | Process for removing trityl blocking groups from 5'-O trityl nucleosides and oligonucleotides | UNIVERSITY PATENTS, INC. (US) | 1981-09-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | MEN1 3300/4885KMT2A 685/4885LTA4H 2776/4885 |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | NT5C3B, CDA, RNGTT | MEN1 3300/4885KMT2A 685/4885LTA4H 2776/4885 |
| US-11332489-B2 | Process for preparing imetelstat | RNGTT, TERT, TRMT1L | MEN1 1496/4885KMT2A 1028/4885LTA4H 1346/4885 |
| US-20200369702-A1 | Improved Process for Preparing Imetelstat | RNGTT, TERT, TRMT1L | MEN1 1495/4885KMT2A 882/4885LTA4H 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.